Acoramidis
- Generic Name
- Acoramidis
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H17FN2O3
- CAS Number
- 1446711-81-4
- Unique Ingredient Identifier
- T12B44A1OE
- Associated Conditions
- -
- Associated Therapies
- -
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Eidos Therapeutics, a BridgeBio company
- Target Recruit Count
- 582
- Registration Number
- NCT06563895
- Locations
- 🇺🇸
National Neuromuscular Research Institute, Austin, Texas, United States
Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04958135
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Efficacy and Safety of Acoramidis (AG10) in Subjects With Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)
Phase 3
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Eidos Therapeutics, a BridgeBio company
- Registration Number
- NCT04882735
A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Eidos Therapeutics, a BridgeBio company
- Target Recruit Count
- 14
- Registration Number
- NCT04769479
- Locations
- 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Eidos Therapeutics, a BridgeBio company
- Target Recruit Count
- 632
- Registration Number
- NCT03860935
- Locations
- 🇺🇸
Piedmont Heart Institute Athens, Athens, Georgia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath